IDEXX Laboratories, Inc. (IDXX) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reflects strong financial performance with increased revenue and EPS guidance. Positive factors include significant growth in CAG Diagnostics, international expansion, and innovation in products like inVue and Cancer Dx. Despite some headwinds in wellness visits and pricing moderation, the overall outlook remains robust with improved margins and strategic expansion plans. The Q&A session confirms these positive trends, with management addressing concerns effectively, leading to a positive sentiment.
Key Financial Performance
Revenue Revenue increased 14% as reported and 12% organically in Q4 2025. This growth was supported by 10% organic growth in CAG Diagnostics recurring revenues and a 69% organic year-over-year expansion of CAG Diagnostic instrument revenues due to record premium instrument placements.
Earnings Per Share (EPS) Q4 EPS was $3.08, up 17% year-over-year on a comparable basis. Full year EPS was $13.08, an increase of 14% year-over-year. The growth was driven by strong operational performance, lower effective tax rate, and foreign exchange benefits.
Operating Margins Full year operating margins reached 31.6%, an increase of 90 basis points on a comparable basis. This was supported by solid revenue expansion and productivity gains.
Free Cash Flow Full year free cash flow was $1.1 billion for 2025, or 100% of net income. This was achieved with capital spending of $125 million, approximately 3% of revenue.
CAG Diagnostics Recurring Revenue Worldwide CAG Diagnostics recurring revenue increased 10% organically in Q4, driven by volume growth and a 4% average global net price improvement. U.S. CAG Diagnostics recurring revenues increased 9% organically, with 4% net price improvement and 5% volume growth.
Instrument Placements In Q4, IDEXX placed 6,567 premium instruments, up 42% from the prior year. For the full year, approximately 22,500 premium instrument placements were achieved, including nearly 6,400 inVue Dx instruments.
Gross Margin Gross profit increased 15% as reported and 13% on a comparable basis in Q4, achieving 60.3%. This was an improvement of 60 basis points comparably, aided by strong consumable growth and higher Reference Lab gross margins.
Rapid Assay Revenues Rapid assay revenues declined 3% on an organic basis in Q4. This was due to pressure on U.S. wellness visits and the transition of pancreatic lipase to Catalyst slides, which had an estimated 4% headwind to Q4 revenue growth.
Reference Lab Revenues Global Reference Lab revenues expanded 9% organically in Q4, supported by solid volume growth and net price improvement. Innovations like IDEXX Cancer Dx contributed to this growth.
Software and Diagnostic Imaging Revenues CAG veterinary software, services, and diagnostic imaging revenues increased 13% organically in Q4, supported by 12% recurring revenues and growth in cloud-based PIMS recurring revenue.
Water Revenues Water revenues increased 10% organically in Q4, with double-digit international revenue growth and solid gains in the U.S.
Livestock, Poultry, and Dairy Revenues Livestock, Poultry, and Dairy revenues increased 4% organically in Q4, supported by solid gains in the Americas.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
inVue Dx: Achieved nearly 6,400 placements in 2025, contributing over $75 million in instrument revenue. It redefines point-of-care cell cytology and includes a controlled launch of fine needle aspirate (FNA) for mast cell tumor detection.
Cancer Dx: Expanded to include canine mast cell tumor detection, with availability expected mid-2026. It also supports early detection and monitoring of canine lymphoma, with an addressable opportunity of approximately 130,000 tests per year in North America.
Catalyst Platform: Introduced Catalyst Pancreatic Lipase and Catalyst Cortisol tests, supporting rapid diagnostics for pancreatitis and endocrine conditions. Adoption exceeded expectations, contributing to consumable growth.
Diagnostic Imaging: Launched an advanced radiography system in early 2026, offering superb image quality and low radiation dose, integrated with AI-powered workflows.
International Expansion: Expanded commercial teams in Germany, the UK, Australia, and the US, reducing account loads per representative and enhancing customer engagement.
Global Premium Instrument Base: Achieved a 12% year-over-year expansion, with nearly 78,000 Catalyst analyzers globally, supporting diagnostics adoption and utilization.
Revenue Growth: Achieved 14% reported and 12% organic revenue growth in Q4 2025, driven by strong CAG Diagnostics recurring revenues and premium instrument placements.
Operating Margins: Full-year operating margins reached 31.6%, up 90 basis points, supported by revenue expansion and productivity gains.
Software Ecosystem: ezyVet and Neo platforms achieved double-digit growth, with record bookings signaling strong momentum. Vello user base grew over 40% from last quarter.
Innovation-Driven Growth: Focused on scaling transformative innovations like inVue Dx and Cancer Dx, and expanding Catalyst platform capabilities.
Customer Retention: Maintained high retention rates in the high 90s for Global CAG Diagnostics, reflecting strong customer loyalty and satisfaction.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Pressure on U.S. clinical visits: U.S. same-store clinical visit declines of approximately 1.7% in Q4 and 1.9% for the full year 2025, with wellness and discretionary visits being more pressured than sick patient visits.
Macroeconomic and sector constraints: Ongoing macroeconomic pressures and sector constraints are expected to continue impacting U.S. same-store clinical visit growth, with a projected decline of approximately 2% in 2026.
Rapid assay revenue decline: Rapid assay revenues declined 3% on an organic basis in Q4, constrained by pressure on U.S. wellness visits and the transition of pancreatic lipase to Catalyst slides, which had an estimated 4% headwind to Q4 revenue growth.
Foreign exchange impacts: Foreign exchange effects had a negative impact on gross margins in Q4 and are expected to have a 60 basis point benefit to full-year revenue growth in 2026, but with sensitivity to currency fluctuations.
Tariff impacts: The company has incorporated impacts of tariffs under current laws into its 2026 outlook, which could affect supply continuity and costs.
Dependency on innovation adoption: The success of new innovations like inVue Dx and Cancer Dx is critical to growth, and slower-than-expected adoption could impact revenue and strategic objectives.
Operational expense increases: Operating expenses increased 11% in Q4 and 10% year-over-year, driven by R&D and commercial investments, which could pressure margins if revenue growth slows.
Sector headwinds in wellness visits: Wellness visits in the U.S. declined 3.6% in Q4, reflecting broader sector challenges that could impact diagnostic frequency and revenue.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
2026 Revenue Guidance: IDEXX projects revenue of $4.632 billion to $4.720 billion, reflecting 7.6% to 9.6% growth on a reported basis and 7% to 9% organic growth.
CAG Diagnostics Recurring Revenue Growth: Expected to grow 8% to 10% organically in 2026, with global net price realization of approximately 4% and U.S. net price improvement of 3.5%. This includes a 2% decline in U.S. same-store clinical visit growth.
Foreign Exchange Impact: Anticipated to provide a 60 basis point benefit to full-year revenue growth, primarily in the first half of 2026.
CAG Instrument Revenue: Projected declines in 2026 due to lapping the rapid expansion of IDEXX inVue Dx instrument placements in 2025.
Operating Margin Outlook: 2026 operating margins are expected to be 32.0% to 32.5%, reflecting a 30 to 80 basis point improvement year-over-year, net of foreign exchange benefits and prior year litigation adjustments.
2026 EPS Guidance: Expected EPS of $14.29 to $14.80, representing a 10% to 14% increase on a comparable basis, net of a 1% reported growth headwind from prior year litigation adjustments.
Free Cash Flow and Capital Spending: 2026 free cash flow conversion ratio is projected at 85% to 95% of net income, with capital spending of $180 million or approximately 4% of revenues.
Q1 2026 Revenue Growth: Projected reported revenue growth of 11.5% to 13.5%, including a 2.5% growth benefit from foreign exchange. Organic revenue growth is expected to be 9% to 11%.
Q1 2026 Operating Margins: Expected to be 31.4% to 31.9%, reflecting solid expansion of comparable margins, net of prior year litigation adjustments and foreign exchange impacts.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase Program: IDEXX allocated $1.2 billion to repurchase 2.4 million shares at an average cost per share of $506, supporting a 2.7% year-over-year reduction in diluted shares outstanding.
2026 Share Repurchase Outlook: The company plans to allocate capital towards share repurchases to support a 1% to 2% year-over-year reduction in diluted shares outstanding while maintaining leverage ratios similar to the past couple of years.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the outlook for wellness versus non-wellness vet visits in 2026, and how are price increases at vet practices evolving?
A:Management noted headwinds on the wellness side, likely due to financial pressures in lower economic demographic households. Non-wellness visits, which represent about 60% of visits and 70-75% of diagnostics revenue, are more resilient and show growth in pets aged 5 years and older. For 2026, a 2% decline in overall visits is expected. On pricing, corporate practices are moderating price increases, which are still above CPI but expected to decrease over time.
Q:What are the drivers of consumables growth, and how does inVue contribute to this growth?
A:Consumables growth is driven by innovation, increased utilization of premium instruments like Catalyst, and the expansion of the installed base (up 12% in 2025). inVue contributes through cell cytology, blood morphology, ear cytology, and FNA for lumps and bumps, with consumables usage tracking to plan. Catalyst placements were strong, with over 1,350 new and competitive placements globally in Q4 2025.
Q:Where is the Reference Lab business seeing growth, and what factors are driving this?
A:The Reference Lab business is growing globally, supported by investments in the lab network, enabling infrastructure, and innovation in areas like fecal antigen and vector-borne disease. Cancer diagnostics are also driving growth, with competitive submissions at approximately 18%.
Q:What is the contribution of innovation like inVue and Cancer Dx to revenue in 2025, and what is expected for 2026?
A:inVue contributed $75 million in revenue in 2025, with consumables usage driving additional growth. Cancer Dx has a modest direct revenue contribution but is expected to grow with the launch of mast cell tumor diagnostics in 2026. The broader innovation strategy has a multiplier effect across the portfolio.
Q:How are pricing dynamics evolving, and what is the feedback from vet clinics?
A:Management noted that pricing is stabilizing, with a 4% total company increase planned for 2026. Vet clinics have not raised significant concerns about pricing, recognizing the need for adjustments during high inflation periods. The focus is shifting back to volume-driven growth.
Q:What is the growth outlook for international CAG Dx recurring revenue compared to the U.S.?
A:International markets are expected to grow faster than the U.S. due to lower diagnostics usage and substantial investments in commercial and infrastructure capabilities. Sustained double-digit growth has been observed in international markets.
Q:Why is Q1 2026 CAG Dx recurring revenue growth guidance lower than the full-year guidance?
A:Q1 guidance reflects a 9.5% growth rate at the midpoint, with a 50 bps days tailwind. Management attributes the lower Q1 growth to clinical visit pressures and pricing dynamics but views the overall growth trajectory as consistent with the full-year outlook.
Q:What is the status of inVue placements in corporate practices, and how does this impact the 2026 guidance?
A:inVue placements in corporate practices are underway, with a longer sell-in cycle compared to independent practices. This is factored into the 2026 guidance, with 5,500 inVue placements targeted for the year.
Q:How is software, including Vello, contributing to results and offsetting market weakness?
A:Software, including Vello, is growing strongly, with double-digit growth in cloud-based PIMS placements. Vello has expanded users by 40%, reducing no-shows and increasing clinical visits and diagnostics usage. While still small compared to the total installed base, software is an important growth driver.
Q:What are the dynamics underpinning gross margin and operating margin improvements in 2026?
A:Gross margin improvements are expected to lead the 30-80 bps operating margin expansion in 2026. Q4 2025 saw 60 bps gross margin expansion, with strong instrument revenues and investments in innovation and commercial capabilities. SG&A growth reflects ongoing investments in the business.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the dollar contribution of Cancer Dx in 2025 and its expected impact in 2026, citing modest direct revenue contributions. Additionally, they did not provide granular data on January 2026 performance or specific metrics for Q1 clinical visits.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CAG Diagnostics
Cancer
Catalyst placement
Diagnostic outlook
Diagnostics revenue
SediVue
Volume
advancement
basis CAG
basis margin
basis net
basis result
benefit IDEXX
benefit exchange
effect share
exchange basis
exchange rate
gain increase
gain platform
headwind litigation
hedge effect
inVue instrument
inVue placement
increase basis
innovation IDEXX
launch inVue
level basis
litigation adjustment
outlook basis
point benefit
point headwind
profit
rate exchange
rate share
realization price
result gain
revenue momentum
revenue result
sector store
segment
share compensation
tax benefit
tax rate
term potential
IDXX Transcript
IDEXX Laboratories, Inc. (IDXX) Presents at Stifel Jaws & Paws Conference 2026 Transcript
Neutral5-27
IDEXX Laboratories, Inc. (IDXX) Q1 2026 Earnings Call Transcript
Positive5-5
IDEXX Laboratories reported strong financial performance with 10% revenue growth, improved operating margins, and a significant increase in net income and EPS. The company also demonstrated strong free cash flow, indicating robust financial health. Despite the lack of strategic updates or risk discussion, the positive financial metrics are likely to lead to a positive stock price movement over the next two weeks.
IDEXX Laboratories, Inc. (IDXX) Presents at 47th Annual Raymond James Institutional Investor Conference Prepared Remarks Transcript
Neutral3-2
IDEXX Laboratories, Inc. (IDXX) Q4 2025 Earnings Call Transcript
Positive2-2
The earnings call reflects strong financial performance with increased revenue and EPS guidance. Positive factors include significant growth in CAG Diagnostics, international expansion, and innovation in products like inVue and Cancer Dx. Despite some headwinds in wellness visits and pricing moderation, the overall outlook remains robust with improved margins and strategic expansion plans. The Q&A session confirms these positive trends, with management addressing concerns effectively, leading to a positive sentiment.
IDXX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
